Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 5
2008 7
2009 2
2010 3
2012 2
2013 2
2014 2
2018 2
2019 1
2020 3
2021 4
2022 4
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Among authors: andreetta c. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines.
Restaino S, Paglietti C, Arcieri M, Biasioli A, Della Martina M, Mariuzzi L, Andreetta C, Titone F, Bogani G, Raimondo D, Perelli F, Buda A, Petrillo M, Greco P, Ercoli A, Fanfani F, Scambia G, Driul L, Vizzielli G; The Udine Hospital Gynecological-Oncological Tumor Board Group. Restaino S, et al. Among authors: andreetta c. Cancers (Basel). 2023 Feb 8;15(4):1091. doi: 10.3390/cancers15041091. Cancers (Basel). 2023. PMID: 36831434 Free PMC article. Review.
Norwegian e-Infrastructure for Life Sciences (NeLS).
Tekle KM, Gundersen S, Klepper K, Bongo LA, Raknes IA, Li X, Zhang W, Andreetta C, Mulugeta TD, Kalaš M, Rye MB, Hjerde E, Antony Samy JK, Fornous G, Azab A, Våge DI, Hovig E, Willassen NP, Drabløs F, Nygård S, Petersen K, Jonassen I. Tekle KM, et al. Among authors: andreetta c. F1000Res. 2018 Jun 29;7:ELIXIR-968. doi: 10.12688/f1000research.15119.1. eCollection 2018. F1000Res. 2018. PMID: 30271575 Free PMC article. Review.
Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?
Macchia G, Titone F, Restaino S, Arcieri M, Pellecchia G, Andreetta C, Driul L, Vizzielli G, Pezzulla D. Macchia G, et al. Among authors: andreetta c. Healthcare (Basel). 2023 Aug 28;11(17):2413. doi: 10.3390/healthcare11172413. Healthcare (Basel). 2023. PMID: 37685447 Free PMC article. Review.
Adjuvant endocrine therapy for early breast cancer.
Andreetta C, Smith I. Andreetta C, et al. Cancer Lett. 2007 Jun 18;251(1):17-27. doi: 10.1016/j.canlet.2006.10.021. Epub 2006 Dec 5. Cancer Lett. 2007. PMID: 17150303 Review.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, Cassani C, Tognon G, Tamberi S, Mangili G, Mammoliti S, De Giorgi U, Greco F, Mosconi AM, Breda E, Artioli G, Andreetta C, Casanova C, Ceccherini R, Frassoldati A, Salutari V, Giolitto S, Scambia G. Lorusso D, et al. Among authors: andreetta c. J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315944 Clinical Trial.
CUP-syndrome: Inguinal high grade serous ovarian carcinoma lymph node metastases with unknown primary origin - a case report and literature review.
Restaino S, Mauro J, Zermano S, Pellecchia G, Mariuzzi L, Orsaria M, Titone F, Biasioli A, Della Martina M, Andreetta C, Poletto E, Arcieri M, Buda A, Driul L, Vizzielli G. Restaino S, et al. Among authors: andreetta c. Front Oncol. 2022 Oct 10;12:987169. doi: 10.3389/fonc.2022.987169. eCollection 2022. Front Oncol. 2022. PMID: 36300091 Free PMC article. Review.
45 results